<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Arielle Le Brenne on Medium]]></title>
        <description><![CDATA[Stories by Arielle Le Brenne on Medium]]></description>
        <link>https://medium.com/@unlockmedtechaccess?source=rss-b95a9b60e23e------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*WnnVzz2vLcmqIHtXhV7rlQ.png</url>
            <title>Stories by Arielle Le Brenne on Medium</title>
            <link>https://medium.com/@unlockmedtechaccess?source=rss-b95a9b60e23e------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 12:50:39 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@unlockmedtechaccess/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Who’s gonna pay for that? Funding BCIs in healthcare]]></title>
            <link>https://medium.com/@unlockmedtechaccess/whos-gonna-pay-for-that-funding-bcis-in-healthcare-dd8262d721aa?source=rss-b95a9b60e23e------2</link>
            <guid isPermaLink="false">https://medium.com/p/dd8262d721aa</guid>
            <category><![CDATA[market-access]]></category>
            <category><![CDATA[brain-computer-interface]]></category>
            <category><![CDATA[health-economics]]></category>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[health-systems]]></category>
            <dc:creator><![CDATA[Arielle Le Brenne]]></dc:creator>
            <pubDate>Thu, 14 Nov 2024 09:02:24 GMT</pubDate>
            <atom:updated>2024-11-14T09:02:24.660Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*cj5oVNakXIXOUH1wOQet9g.png" /></figure><p>I realised I’d lost the person I was speaking with.</p><p>We were discussing brain computer interfaces (BCIs) making headlines recently [<a href="https://www.bloomberg.com/news/articles/2024-10-29/spanish-startup-inbrain-raises-50-million-for-brain-device">1</a>,<a href="https://www.massdevice.com/onward-third-brain-computer-interface-implant/">2</a>], but judging by his glazed expression, I had clearly gone on too long. ‘What do you think?’ I asked. There was a long pause before he replied, ‘Do you think health systems will pay for that?’</p><p>Good question.</p><p>To me, BCIs represent a new frontier in how health systems fund medical devices. They have the potential to treat neurological disorders, improve mental health conditions, and revolutionise prosthetics [<a href="https://www.sciencedirect.com/science/article/pii/S1878875024008672?via%3Dihub">3</a>, <a href="https://www.forbes.com/sites/johnwerner/2024/08/23/pioneering-depression-treatment-with-groundbreaking-brain-computer-interface-bci--ai/">4</a>, <a href="https://www.apa.org/news/podcasts/speaking-of-psychology/brain-computer-interfaces">5</a>]. However, their high cost, relative lack of long-term data, and concerns about privacy and security could make health system payers hesitate to reimburse, creating a significant barrier to patient access.</p><p>BCI startups may find themselves facing these scenarios:</p><ul><li>Their technology exceeds a health system’s cost-effectiveness threshold</li><li>Current preferred methods to measure quality of life do not fully capture benefits</li><li>Approvals are delayed due to uncertainties about privacy and data safeguarding</li></ul><p>All of these highlight the unique market access challenge BCI startups face: their technology is advancing rapidly but the frameworks to enable adoption are lagging behind.</p><p>So, back to the question of whether health systems will pay for BCIs.</p><p>Some will.</p><p>Why? Because the economic challenge of the conditions they treat is too significant for many governments to ignore.</p><p>For instance, neurological disorders affect more than 3 billion people worldwide [<a href="https://www.who.int/news/item/14-03-2024-over-1-in-3-people-affected-by-neurological-conditions--the-leading-cause-of-illness-and-disability-worldwide">6</a>]. In the UK alone, neurological disorders cost the economy around £96 billion annually in direct costs to the health system and indirect losses in productivity from affected individuals and their caregivers [<a href="https://impact.economist.com/perspectives/sites/default/files/ei_the_value_of_action_mitigating_the_impact_of_neurological_disorders_in_the_united_kingdom_report_v4_17-5-24_r1.pdf">7</a>]. There is also high unmet need in current treatments [<a href="https://www.nature.com/articles/s41582-023-00808-z">8</a>].</p><p>In a market like the UK, a BCI that treats a neurological disorder would be evaluated against existing interventions to determine its cost-effectiveness. However, an absence of long-term data could mean that reimbursement decisions are conditional. The UK’s health technology assessment body, the National Institute for Health and Care Excellence (NICE), might recommend a BCI for NHS-funded treatment under a data collection agreement, similar to approaches used for some medications [<a href="https://www.nice.org.uk/about/what-we-do/our-programmes/managed-access">9</a>]. Other health systems might follow suit or explore additional innovative payment models. This is the aforementioned new frontier in medical device funding.</p><p>The above said, there are also health systems will not fund.</p><p>Health systems are under immense financial strain and the cost of a BCI could exceed what some systems are willing to pay. In these cases, private health insurers might step in to provide coverage, or patients may need to pay out-of-pocket. While this could improve access, it also risks deepening inequalities in the treatment of conditions BCIs target, like those already seen in neurological disorders [<a href="https://www.nature.com/articles/s41582-023-00808-z">8</a>].</p><p>BCI startups will navigate an uncertain and complex reimbursement landscape. However, they can look to another neurotechnology that faced similar challenges: cochlear implants.</p><p>When cochlear implants were first introduced, they encountered many of the same barriers now facing BCIs, such as no reimbursement, limited data on long-term outcomes, and a lack of awareness among payers. However, through successful advocacy and growing evidence of their impact, cochlear implants eventually gained widespread reimbursement and funding [<a href="https://www.cms.gov/medicare/coverage/evidence/cochlear">10</a>, <a href="https://www.nice.org.uk/guidance/ta566">11</a>].</p><p>Which brings me back to the response I gave my colleague: “Sure health systems would pay, look at what happened with cochlear implants.”</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=dd8262d721aa" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Market Access 101: 5 Tips for Beginners]]></title>
            <link>https://medium.com/@unlockmedtechaccess/market-access-101-5-tips-for-beginners-fe8afda495e5?source=rss-b95a9b60e23e------2</link>
            <guid isPermaLink="false">https://medium.com/p/fe8afda495e5</guid>
            <category><![CDATA[healthtech]]></category>
            <category><![CDATA[pharmaceuticals-industry]]></category>
            <category><![CDATA[medtech]]></category>
            <category><![CDATA[market-access-strategy]]></category>
            <category><![CDATA[market-access]]></category>
            <dc:creator><![CDATA[Arielle Le Brenne]]></dc:creator>
            <pubDate>Tue, 19 Sep 2023 08:17:44 GMT</pubDate>
            <atom:updated>2023-09-19T08:17:44.822Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*S4MXCtwo1Hk1VkrVKKejVg@2x.jpeg" /><figcaption>Photo by Clemens van Lay on Unsplash</figcaption></figure><p>Working on market access can feel daunting for beginners. This field is incredibly multifaceted, requiring you to navigate complex healthcare systems, champion patient access, and address intricate clinical and economic requirements. So, where should you begin?</p><p>In this article, I’ll share five tips to help you not only get started but also succeed in your market access journey. These tips are universally applicable, whether you find yourself in a multinational pharmaceutical or MedTech company, a consultancy, or at the helm of a startup.</p><h3>1. Look at the Big Picture</h3><p>When you’re just starting, the temptation is to dive headfirst into building your knowledge, especially in areas such as health economics or reimbursement. However, resist that urge (temporarily) and instead, take a step back to view your work from these two crucial perspectives:</p><h4>a. Business impact (internal focus)</h4><p>Beyond reviewing your company’s strategy, collaborate with teams from different business functions to understand how patient access (or the lack thereof) affects sales, evidence generation, marketing messaging, and more.</p><h4>b. Customer impact (external focus)</h4><p>Macro trends play an important role in payer and provider decision making. Learn about the current priorities within the health system and any existing national policies related to the disease or condition your product addresses. Understand where your product fits into the broader landscape.</p><h3>2. Build relationships</h3><p>While a wealth of information about treatment pathways, reimbursement, and health system dynamics is available online, the most valuable insights come from engaging with those directly impacted by these factors on a daily basis.</p><p>In addition to collaborating with internal teams (as mentioned in the point above), seek opportunities to build relationships with healthcare professionals, payers, and advocacy groups.</p><h3>3. Communicate Value Effectively</h3><p>Effectively conveying the value of your products, both to customers and within your organisation, is paramount to your success. Consider the following when communicating value:</p><ul><li>Assume no one is an expert. For example, payers or hospital finance teams may only have a high level understanding of a treatment area. Clearly explain the disease/condition, treatment, and the value your product brings</li><li>Use language that resonates with your customers</li><li>Make sure internal teams are on the same page. For example, do they know whom payers refer to?</li></ul><h3>4. Make a Persuasive Case</h3><p>Market Access is sales. It entails persuading decision-makers to pay for and adopt products, which directly impacts the bottom line.</p><p>Crafting a persuasive case for your customers involves connecting the dots between their needs and your product, as well as setting your product apart from the competition. This is where one of the most critical roles of market access comes into play: articulating the value of your products. When assessing a product, ask yourself and consult with specialists on your team:</p><ul><li>How would the product deliver value to patients, healthcare professionals, providers, and payers?</li><li>How could the value be substantiated?</li><li>Would be a payer be willing to pay for the product’s value?</li><li>What will drive product adoption?</li></ul><h3>5. Remember Reimbursement Isn’t the End Goal</h3><p>Securing product reimbursement can be a lengthy and challenging process. However, remember that reimbursement is just the first step and doesn’t guarantee adoption. Even with reimbursement, your product may encounter hurdles like inconsistent adoption among providers or have reimbursement contingent on quantifying the value delivered to the healthcare system. Anticipate these challenges and incorporate them into your access plan.</p><h3>Final Thoughts</h3><p>Achieving success in market access requires a versatile skill set that includes value selling, strategy development, and effective communication. Regardless of your background, I hope these tips both help you get started and also empower you to cultivate a lasting momentum for success.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fe8afda495e5" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Got a MedTech business challenge? Try these 3 Lean Six Sigma tools]]></title>
            <link>https://medium.com/@unlockmedtechaccess/got-a-medtech-business-challenge-try-these-3-lean-six-sigma-tools-6c37b89d6c43?source=rss-b95a9b60e23e------2</link>
            <guid isPermaLink="false">https://medium.com/p/6c37b89d6c43</guid>
            <category><![CDATA[medtech]]></category>
            <category><![CDATA[healthtech]]></category>
            <category><![CDATA[continuous-improvement]]></category>
            <category><![CDATA[business-challenges]]></category>
            <category><![CDATA[lean-six-sigma]]></category>
            <dc:creator><![CDATA[Arielle Le Brenne]]></dc:creator>
            <pubDate>Tue, 13 Jun 2023 06:47:12 GMT</pubDate>
            <atom:updated>2023-06-13T06:47:12.660Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*xurfPxPTBTtlp3kw" /><figcaption>Photo by <a href="https://unsplash.com/it/@_staticvoid?utm_source=medium&amp;utm_medium=referral">Lucas Santos</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p>If you’re wondering whether Lean Six Sigma (LSS) is only used in manufacturing, you’re not alone. When my former boss introduced it as a way to enhance my work commercialising MedTech, I pictured myself on a factory assembly line. However, over the years, I’ve discovered that LSS’ customer-centric approach is incredibly valuable for MedTech businesses, particularly when the customer includes patients, healthcare professionals, providers, payers, and policy makers.</p><p>In this blog post, I’ll discuss three common MedTech business challenges and the LSS tools that can help you find solutions. Don’t worry, we won’t dive into complex concepts. These tools are accessible and require no specific training. However, if you’re interested in learning more, check out the post script. So, without further ado…</p><h3>Challenge 1: What does the customer really want?</h3><p>Every company strives to answer this question, but some make the mistake of relying on guesswork, which can lead to the creation of products or services that fail to meet customer needs. To help prevent this from happening, it’s important to capture the Voice of the Customer (VOC). VOC refers to the exact words and feedback directly from customers, leaving no room for ambiguity regarding their expectations, preferences, or opinions.</p><p>Once you know what the customer wants, the next step is determining <strong><em>how</em> </strong>to address their needs. A powerful LSS tool to bridge this gap is a Critical to Quality (CTQ) tree, which I’ll explain in detail below:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*pey5iF_YID_qIOWgZs1SZw.png" /><figcaption>© Arielle Le Brenne 2023</figcaption></figure><p>Establishing the customer’s CTQs not only forms a solid foundation for developing solutions but also offers an added advantage during the solution ideation phase by maintaining team focus. During this phase, distractions and differing opinions can emerge, potentially causing delays. However, CTQs act as a constant reminder of the project’s requirements, ensuring everyone stays on track and sustains progress.</p><h3>Challenge 2: How do I begin solving this problem?</h3><p>When it comes to solving a problem or achieving a goal, figuring where to start can be overwhelming. This is where gaining perspective and creating a solid action plan becomes crucial. Enter the thought map, a LSS tool that helps you visually organise all the information, thoughts, and questions related to a project or goal. It enables you to take a step back, gain clarity, and start breaking down the task into manageable chunks.</p><p>To get started, here is a guide to creating a thought map:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1013/1*0XnW7nrdcxBqObL-PDHpxg.png" /><figcaption>© Arielle Le Brenne 2023</figcaption></figure><p>Once you’ve created your thought map, consider it a living document that evolves with your project. Feel free to continually add relevant information as new insights emerge or the project progresses. And remember, there is no set format for a thought map. The key is to find a format that works best for you and enables you to effectively capture and organise your thoughts.</p><h3>Challenge 3: Is the current process adding value?</h3><p>The world of MedTech is full of intricate processes with multiple interdependencies, both in healthcare settings and within companies. To develop solutions, these processes are often mapped to determine whether the current way of doing things is adding value for customers. For instance, a treatment pathway, which itself is a process, is analysed to identify opportunities for improving patient care.</p><p>While flow charts are useful to a certain extent, they do not fully capture the complexities of healthcare and MedTech processes. This is where the LSS process map comes in. Similar to a flow chart, it allows you to map a process into steps. However, it goes beyond that by visualising interdependencies and evaluating whether each step truly adds value for the customer(s). Think of it as an advanced flow chart, as outlined below:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*EPSiRTrYYj8h6_JCTcKYdA.png" /><figcaption>© Arielle Le Brenne 2023</figcaption></figure><p>A potential obstacle in developing a process map is identifying which steps add value and which ones do not. There is a LSS definition of value but my perspective stems from business development/sales. To me, value encompasses anything that assists customers in resolving issues, achieving tasks or goals, or avoiding problems. Conversely, any step that does not meet this criteria is non-value adding. In the example above, faxing the patient’s test results could be considered non-value adding since the results are already accessible to the doctor through the patient’s medical record. However, I recommend as a follow up to any process map to explore <strong><em>why</em></strong> non-value adding steps are done but that’s another blog post.</p><h3>Final Thoughts</h3><p>LSS offers a treasure trove of powerful and practical tools to help overcome common challenges faced by MedTech businesses. However, their true value goes beyond their functionalities. They cultivate a customer-centric mindset and problem-solving approach that are crucial for companies navigating the ever-evolving healthcare landscape. So by experimenting with these tools, you not only tackle challenges head-on but also unlock a wealth of additional benefits that will propel your business forward.</p><h4>Post Script: Find out more</h4><p>When it comes to all things LSS, I’ve found <a href="https://www.isixsigma.com/">iSixSigma</a> to be an invaluable resource. Use their search function to learn more about LSS and find best practice guides that can assist you in effectively implementing the tools we’ve discussed.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6c37b89d6c43" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Accelerate Your MedTech Startup Growth with a Market Access Strategy]]></title>
            <link>https://medium.com/@unlockmedtechaccess/accelerate-your-medtech-startup-growth-with-a-market-access-strategy-8f50295d236e?source=rss-b95a9b60e23e------2</link>
            <guid isPermaLink="false">https://medium.com/p/8f50295d236e</guid>
            <category><![CDATA[startup-growth]]></category>
            <category><![CDATA[medtech]]></category>
            <category><![CDATA[commercialization]]></category>
            <category><![CDATA[market-access-strategy]]></category>
            <category><![CDATA[market-access]]></category>
            <dc:creator><![CDATA[Arielle Le Brenne]]></dc:creator>
            <pubDate>Tue, 11 Apr 2023 06:01:50 GMT</pubDate>
            <atom:updated>2023-05-04T21:53:45.116Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Qg-hAajGR2FhHN8P" /><figcaption>Photo by <a href="https://unsplash.com/@nasa?utm_source=medium&amp;utm_medium=referral">NASA</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p>The #1 challenge MedTech startups face is getting a product to patients. Before you ask ‘what about funding?’, hear me out. You can have a lot of funding but if access to a product is blocked in any way commercial success will be limited.</p><p>Understanding the requirements for eligible patients to access a product is critical for successful commercialisation. This is where a market access strategy comes in. It maps these requirements and also anticipates what could limit access, such as:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Lfrn6VeQ7cgBxKwANwcQAQ.png" /></figure><h3>Creating a strategy to unlock access</h3><p>Ideally a market access strategy is created during product development. Asking early on strategic questions such as ‘would a health system/insurer/patient pay for this product?’ or ‘how can we prove the value proposition?’ could save you a lot of time.</p><p>The reality is most strategies are developed <strong>after</strong> regulatory approval. With this in mind, let’s focus on a strategy to meet the following objectives:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*CkY3CmQYsMosum-Va-6-Xg.png" /></figure><p>Like any strategy, a market access strategy starts with asking critical questions. To kick start the process, here are some questions to ask:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4tUvNHufk1ryWiQ5xqe9aA.png" /></figure><p>There’s a wealth of information out there to help answer the questions above and the additional questions you’ll have. Building from this you can start to develop a market access strategy and execution plan tailored to your product. This will depend on the following factors (not exhaustive):</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*oikHirPyuB40Moid1jsFHg.png" /></figure><p>As with all strategies, a market access strategy evolves. So far, we’ve discussed on addressing immediate requirements but later your focus might be sustaining market access. The key here is to stay informed and ready to adapt your strategy to changing market and stakeholder needs.</p><h3>Final thoughts</h3><p>Having a market access strategy is crucial for MedTech companies to achieve commercial success. It helps identify the factors that enable or hinder patient access, paving the way for successful product launch, adoption, and sustained market presence. By developing and executing a well-crafted market access strategy (as early as possible), you can unlock your product’s full potential in today’s complex healthcare environment.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8f50295d236e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[I asked ChatGPT about Market Access, here’s what happened]]></title>
            <link>https://medium.com/@unlockmedtechaccess/i-asked-chatgpt-about-market-access-heres-what-happened-c8b670f9cb93?source=rss-b95a9b60e23e------2</link>
            <guid isPermaLink="false">https://medium.com/p/c8b670f9cb93</guid>
            <dc:creator><![CDATA[Arielle Le Brenne]]></dc:creator>
            <pubDate>Mon, 13 Feb 2023 14:33:44 GMT</pubDate>
            <atom:updated>2023-02-21T10:20:09.330Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*ytui8X95Lhe6G-eY" /><figcaption>Photo by <a href="https://unsplash.com/@jupp?utm_source=medium&amp;utm_medium=referral">Jonathan Kemper</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p>I knew nothing about market access when I got approached for my first role. I had unsuccessfully applied for a product management position and then got a call back asking if I’d be interested in a market access role. “Of course” I said trying to sound as cool as possible. The second the call ended I quickly typed into Google <strong><em>what is market access?</em></strong></p><p>What stands out most for me from that experience (besides the anxiety) was how difficult it was to find a concise answer. These days there’s more market access resources available on the internet but you still need to pull together information from different sites to get a complete picture.</p><p>Over the last weeks, ChatGPT has emerged as a powerful <em>contextualiser </em>of information. As an experiment I wanted to see whether it could bring all market access resources together to create an explainer. To find out, I asked ChatGPT the following questions: <strong>Why do MedTech companies need market access?</strong> and <strong>How do I create a market access strategy for a medical technology? </strong>I was generally impressed by the responses which you can find at the end of this post with commentary (I also marked its efforts!)</p><p>The interesting part, however, came after.</p><p>I challenged ChatGPT on its responses and asked for specific examples. The subsequent responses made me realise I was just scratching the surface for how it can be used in market access. I summarised some ideas on its potential below:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*t82doIIpoi9WnkuJk-6k1g.png" /></figure><p>My conclusion from this experiment is that ChatGPT can not only effectively explain market access but also be a useful tool for <strong><em>anyone </em></strong>working in this area. Its value goes beyond collating information and it can also provide frameworks for market access strategy and execution. This then enables the user to build upon these frameworks to create tailored market access strategies and plans.</p><p>ChatGPT’s utility in market access, or any area for that matter, will depend on whether you can effectively tap into its full potential. At heart, it is a chatbot that’s been trained on billions of data points. Therefore, the key to getting the most out of ChatGPT is to formulate questions and prompts to unlock the power of that data and its corresponding neural networks.</p><h3>Post script: ChatGPT Explains Market Access</h3><p>These are ChatGPT’s responses to the two questions I asked about market access and an assessment on whether they deliver.</p><h4>1. Why do MedTech companies need market access?</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*X0vL1v0x7Mhueqa-tcro7Q.png" /></figure><p>What’s great about this response is that, in explaining <strong><em>what is market access?</em></strong>, the value of market access to patients and providers is highlighted. However, it only mentions short-term market access activities (approval, reimbursement). What would improve this response is a line on long-term activities, such as sustaining reimbursement and what’s involved.</p><p><strong>Verdict:</strong> 8/10</p><h4>2. How do I create a market access strategy for a medical technology?</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/803/1*MvE9JWFq666r70TTt0vIMw.png" /></figure><p>If I was interviewing now for a market access role with zero background, I’d ask this question. While the response is not a market access strategy, it does provide decent framework for planning <em>some</em> pre and post product launch activities. That is, a good market access strategy is tailored to the needs of a heath system, stakeholders, product, etc. For example, if a product is disruptive and requires a change to the treatment pathway then that must be factored into its market access strategy.</p><p><strong>Verdict:</strong> 0/10 for strategy, 9/10 for activity planning</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c8b670f9cb93" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Don’t overlook change management in your MedTech launch plans]]></title>
            <link>https://medium.com/@unlockmedtechaccess/dont-overlook-change-management-in-your-medtech-launch-plans-9b45cb82af90?source=rss-b95a9b60e23e------2</link>
            <guid isPermaLink="false">https://medium.com/p/9b45cb82af90</guid>
            <category><![CDATA[market-access]]></category>
            <category><![CDATA[strategy]]></category>
            <category><![CDATA[medtech]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Arielle Le Brenne]]></dc:creator>
            <pubDate>Sun, 15 Jan 2023 21:11:53 GMT</pubDate>
            <atom:updated>2023-01-15T21:11:53.281Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*b750R0_dBQj8a2XV" /><figcaption>Photo by <a href="https://unsplash.com/@rossf?utm_source=medium&amp;utm_medium=referral">Ross Findon</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p>When launching a product, the most common approach companies take is delivering training and then leaving implementation to the customer. Where this approach falls short is that customers (healthcare professionals and providers in this context) are left to navigate the challenges that come with introducing a new product into practice on their own, particularly people’s resistance to changing the status quo.</p><p>Incorporating basic elements of change management into a MedTech launch plan helps companies anticipate these challenges and, more importantly, identify potential solutions.</p><p>How can you incorporate change management into a launch plan? Here are 5 change management concepts to consider:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*G8ydsdA2mP9W_LXG1-N6ZQ.png" /></figure><p>More on each below..</p><h4><strong>1.</strong> <strong>Make a case for change</strong></h4><p>People decide to change when they realise their current situation is untenable. This is no different in a healthcare setting. Articulating <em>why</em> an existing way of delivering care should change is the first step in creating a compelling case for change to persuade customers and decision makers considering your product. To do this, try to collect information on the following:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*B4Swmdl5N_S-H6MVJMxuIg.png" /></figure><p>Once you’ve built your case, have it on standby ready for marketing materials, training, or any ad hoc information requests.</p><h4><strong>2.</strong> <strong>Engage ALL stakeholders</strong></h4><p><em>Any</em> person impacted by your product is a stakeholder who can influence whether or not your product is successfully adopted. They need to be accounted for from initial introduction to product training and implementation support. Not involving a stakeholder in these changes means missing out not only on important information/insights but also gaining their early buy-in for your product.</p><p>Here is a way to avoid missing stakeholders:</p><ul><li>Start by creating a list of all the persons you think need to be involved in introducing your product</li><li>You will not know all the potential stakeholders so have your list sense-checked by the customer</li><li>Once your list is finalised, think about the needs of each stakeholder and how best to engage</li></ul><h4><strong>3.</strong> <strong>Remove obstacles</strong></h4><p>Introducing a new product into clinical use involves a lot of coordinated work; protocols need to be updated, approval forms completed, patients informed, etc. This can be overwhelming as it adds to existing workloads.</p><p>Help remove any obstacles for your customers by asking them what’s something they really could use assistance with now, or potentially in the future, and whether you can support.</p><h4><strong>4.</strong> <strong>Find root causes of resistance</strong></h4><p>You will have stakeholders who do not want to change the status quo. How this reluctance manifests itself differs person to person but it will be clear they’re not on board. Irrespective of what the person does, there is an underlying concern or issue that must be addressed as this risks the success of your product’s adoption.</p><p>When resistance occurs, engage the person either one-to-one or facilitated by another stakeholder and seek to understand their concerns. Common root causes include technical issues with your product, being unaware why the change is occurring, and being uninvolved in the changes made (several more root causes described <a href="https://www.prosci.com/resources/articles/tips-for-managing-resistance-to-change">here</a>). While it’s worth keeping these in mind, suspend judgment in your discussions to find the root cause. Once you have, work to address the person’s concerns and provide additional support where needed.</p><h4><strong>5.</strong> <strong>Facilitate knowledge sharing</strong></h4><p>Customers will want to learn from other customers the clinical and operational benefits of using your product, as well as their implementation experience.</p><p>There are two ways to facilitate this type of knowledge sharing. The first, and most straightforward, is to ask a customer who has adopted your product if they are OK to be contacted by another customer and, if they are, introduce them to one another. The second only works if your product has been successfully used for a longer time and it is to create a case study. A case study in this context is a type of marketing that provides a snapshot of a customer’s experience in adopting a MedTech solution. Case studies answer these questions:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Ef30Em0PxxqA4gu2usRKXw.png" /></figure><p>Developing a case study involves a lot of work but the payoff is worth it in terms of identifying usable best practices, helping your customers put together their own data, and creating promotional material.</p><p>Whichever method you choose, make it a point to collect data as early as possible to quantify the impact of your product.</p><p>Customers will put in time and effort into adopting a new product into practice. Therefore, its paramount they understand why current ways of working are changing, how it benefits them, and that they are supported and listened to throughout the process. Applying change management strategies, like those described above, addresses these needs. Moreover, supporting teams through the change helps identify best practices and improvement opportunities to apply to future launches.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9b45cb82af90" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>